Topically active steroids for use in interstitial pulmonary fibrosis
AssigneeSoligenix, Inc.
InventorGeorge B. McDonald
Life of this patent
Estimating the term…
Abstract
The present invention features methods of delivering corticosteroids or metabolites thereof for treating inflammatory conditions otherwise difficult to cure with topical administration.
Claims9
A method of treating an interstitial lung disease comprising oral delivery such that oral delivery consists of oral ingestion of an effective amount of a locally active topical active corticosteroid sufficient to expose a metabolite thereof to the pulmonary circulation of a subject, wherein the locally active topical active corticosteroid is beclomethasone dipropionate and further wherein the metabolite found in the systemic circulation is 17-beclomethasone monopropionate.
A method of delivering a locally active topical active corticosteroid or metabolite thereof to a subject's pulmonary artery for treatment of an interstitial lung disease by administering to the subject an effective amount of an oral dosage such that administration consists of oral ingestion of the corticosteroid or metabolite, wherein the locally active topical active corticosteroid is beclomethasone dipropionate and further wherein the metabolite found in the systemic circulation is 17-beclomethasone monopropionate.
A method for preventing, ameliorating and/or treating damage resulting from an interstitial lung disease, the method comprising delivering to a subject's pulmonary artery a metabolite of an orally administered locally active topical active corticosteroid such that oral administration consists of oral ingestion in a dose that is greater than the corticosteroid delivered via inhalation, wherein the topical active corticosteroid is beclomethasone dipropionate and further wherein the metabolite found in the systemic circulation is 17-beclomethasone monopropionate.
Dependencies are inferred from the claim text.